EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial

Rino Alvani Gani iD, Pitt Akbar iD, Irsan Hasan iD, Andri Sanityoso Sulaiman iD, Cosmas Rinaldi Adithya Lesmana iD, Juferdy Kurniawan iD, Sarah Melissa Panjaitan, Valerie Josephine Dirjayanto iD

Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (4) · 458-470

DOI: 10.1111/apt.70811 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-07-07. Written by Rino Alvani Gani and 7 co-authors. Institution: Hepatobiliary Division, Internal Medicine Department, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jak…. Major MEDLINE topics: Liver Cirrhosis, Pyridines, Pyrimidines, Sleep Initiation and Maintenance Disorders. Cited 4 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Eisai Indonesia.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and Aim No pharmacologic treatment has yet been approved for sleep disturbances in cirrhosis, a high‐risk group with substantial prevalence and clinical consequences. Lemborexant has shown efficacy for insomnia, but evidence in cirrhosis is limited.

Methods

Restoring Sleep in End‐Stage Liver Disease (RESTORE) is a prospective, double‐blind, placebo‐controlled, crossover trial of Lemborexant for patients with cirrhosis in Cipto Mangunkusumo National Referral Hospital. We randomized 82 patients into three arms: Placebo ( n = 28), 5 mg Lemborexant ( n = 28), and 10 mg Lemborexant ( n = 26). Efficacy was assessed via Pittsburgh Sleep Quality Index (PSQI) over a 2‐week period. Safety was evaluated using the EncephalApp Stroop Test for hepatic encephalopathy and liver function tests including AST, ALT, and total bilirubin. PSQI was reevaluated post‐crossover at week 4 to investigate rebound insomnia.

Results

Lemborexant significantly reduced PSQI at week 2 in both 5 mg (MD: −7.0 ± 3.15; p < 0.001) and 10 mg groups (MD: −8.27 ± 2.68; p < 0.001), indicating better sleep quality. The 5 mg group showed improved Stroop Test reaction time (MD: −23.5 ± 31.3; p < 0.001), suggesting better cognitive function, whereas 10 mg showed a mild but significant increase in reaction time (MD: 16.7 ± 41.3; p = 0.048). Liver function was not different across treatment groups. Post‐crossover analysis showed persistent low PSQI scores in active groups who were switched to placebo. Patients who initially received placebo demonstrated improved sleep after receiving Lemborexant.

Conclusion

Our study supported the efficacy and safety of Lemborexant, particularly at 5 mg, against sleep problems in cirrhosis. Larger studies with longer follow‐up are warranted to strengthen evidence. ClinicalTrials.gov: NCT07480096.

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisPyridinesPyrimidinesSleep Initiation and Maintenance DisordersOrexin Receptor AntagonistsAdultAgedFemaleHumansMaleMiddle AgedCross-Over StudiesDouble-Blind MethodProspective StudiesSleep QualityTreatment Outcome

Author keywords

Pittsburgh Sleep Quality Indexhepatic encephalopathyhepatic safetyliver cirrhosisorexin receptor antagonists

Substances

lemborexantPyridinesPyrimidinesOrexin Receptor Antagonists

Authors and institutions

  • Hepatobiliary Division, Internal Medicine Department, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

ORCID profiles: Rino Alvani Gani, Pitt Akbar, Irsan Hasan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Valerie Josephine Dirjayanto

Funding

  • Eisai Indonesia

Cite

APA

Gani, R. A., Akbar, P., Hasan, I., Sulaiman, A. S., Lesmana, C. R. A., Kurniawan, J., Panjaitan, S. M., & Dirjayanto, V. J. (2026). Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial. Alimentary Pharmacology & Therapeutics, 64(4), 458-470. https://doi.org/10.1111/apt.70811

Vancouver

Gani RA, Akbar P, Hasan I, Sulaiman AS, Lesmana CRA, Kurniawan J, et al. Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial. Alimentary Pharmacology & Therapeutics. 2026;64(4):458-470. doi:10.1111/apt.70811

BibTeX
@article{Gani2026,
  author = {Gani, Rino Alvani and Akbar, Pitt and Hasan, Irsan and Sulaiman, Andri Sanityoso and Lesmana, Cosmas Rinaldi Adithya and Kurniawan, Juferdy and Panjaitan, Sarah Melissa and Dirjayanto, Valerie Josephine},
  title = {Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {4},
  pages = {458--470},
  doi = {10.1111/apt.70811}
}
Start for free →